BACKGROUND: Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both pericytes and endothelial cells. METHODS: We have designed a 3+3 dose-escalating phase I trial with a fixed dose of MC (50 mg two times daily) plus IM (400 mg per day; 300 and 400 mg two times daily). Enrolled patients had IM- and sutininib-refractory advanced gastrointestinal stromal tumours (GIST) (n=17), chordoma (n=7) and mucosal melanoma (n=2). Dose-limiting toxicities were monitored for the first 6 weeks. Progression-free survival (PFS) and response assessment are based on RECIST 1.0 guidelines. Pharmacokinetics of IM were measured before and after exposure to MC. RESULTS: No dose-limiting toxicity was observed. Fourteen patients of the expanded cohort received 400 mg two times daily of IM with MC. Apart from a case of possibly related acute leukaemia occurring after 4 years of treatment, we did not see unexpected toxicity. No drug-drug pharmacokinetic interaction was observed. There was no objective response. We have observed long-lasting stable disease in chordoma patients (median PFS=10.2 months; range, 4.2-18+) and short-term stable disease in heavily GIST pretreated patients (median PFS=2.3 months; range, 2.1-6.6). CONCLUSION: This combination is feasible and may warrant further exploration in refractory GIST or chordoma patients.
BACKGROUND: Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both pericytes and endothelial cells. METHODS: We have designed a 3+3 dose-escalating phase I trial with a fixed dose of MC (50 mg two times daily) plus IM (400 mg per day; 300 and 400 mg two times daily). Enrolled patients had IM- and sutininib-refractory advanced gastrointestinal stromal tumours (GIST) (n=17), chordoma (n=7) and mucosal melanoma (n=2). Dose-limiting toxicities were monitored for the first 6 weeks. Progression-free survival (PFS) and response assessment are based on RECIST 1.0 guidelines. Pharmacokinetics of IM were measured before and after exposure to MC. RESULTS: No dose-limiting toxicity was observed. Fourteen patients of the expanded cohort received 400 mg two times daily of IM with MC. Apart from a case of possibly related acute leukaemia occurring after 4 years of treatment, we did not see unexpected toxicity. No drug-drug pharmacokinetic interaction was observed. There was no objective response. We have observed long-lasting stable disease in chordomapatients (median PFS=10.2 months; range, 4.2-18+) and short-term stable disease in heavily GIST pretreated patients (median PFS=2.3 months; range, 2.1-6.6). CONCLUSION: This combination is feasible and may warrant further exploration in refractory GIST or chordomapatients.
Authors: Daniel D Von Hoff; Joseph J Stephenson; Peter Rosen; David M Loesch; Mitesh J Borad; Stephen Anthony; Gayle Jameson; Susan Brown; Nina Cantafio; Donald A Richards; Tom R Fitch; Ernesto Wasserman; Cristian Fernandez; Sylvan Green; William Sutherland; Michael Bittner; Arlet Alarcon; David Mallery; Robert Penny Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Christiane D Thienelt; Paul A Bunn; Nasser Hanna; Arthur Rosenberg; Michael N Needle; Michael E Long; Daniel L Gustafson; Karen Kelly Journal: J Clin Oncol Date: 2005-10-24 Impact factor: 44.544
Authors: Christopher J Sweeney; E Gabriela Chiorean; Claire F Verschraegen; Fa Chyi Lee; Suzanne Jones; Melanie Royce; Lesley Tye; Katherine F Liau; Akintunde Bello; Richard Chao; Howard A Burris Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544
Authors: N Penel; S Clisant; E Dansin; C Desauw; M Dégardin; L Mortier; M Vanhuyse; F Bonodeau; C Fournier; J-L Cazin; A Adenis Journal: Br J Cancer Date: 2010-03-30 Impact factor: 7.640
Authors: P Hamberg; N Steeghs; W J Loos; D van de Biessen; M den Hollander; M Tascilar; J Verweij; H Gelderblom; S Sleijfer Journal: Br J Cancer Date: 2010-05-18 Impact factor: 7.640
Authors: Wells A Messersmith; Daniel A Laheru; Neil N Senzer; Ross C Donehower; Paula Grouleff; Theresa Rogers; Sean K Kelley; David A Ramies; Bert L Lum; Manuel Hidalgo Journal: Clin Cancer Res Date: 2004-10-01 Impact factor: 12.531
Authors: S Stacchiotti; E Tamborini; S Lo Vullo; F Bozzi; A Messina; C Morosi; A Casale; F Crippa; E Conca; T Negri; E Palassini; A Marrari; E Palmerini; L Mariani; A Gronchi; S Pilotti; P G Casali Journal: Ann Oncol Date: 2013-04-04 Impact factor: 32.976
Authors: Sabine Taschner-Mandl; Magdalena Schwarz; Johanna Blaha; Maximilian Kauer; Florian Kromp; Nelli Frank; Fikret Rifatbegovic; Tamara Weiss; Ruth Ladenstein; Martin Hohenegger; Inge M Ambros; Peter F Ambros Journal: Oncotarget Date: 2016-01-19
Authors: Diane Pannier; Antoine Adenis; Emilie Bogart; Eric Dansin; Stéphanie Clisant-Delaine; Emilie Decoupigny; Anne Lesoin; Eric Amela; Sandrine Ducornet; Jean-Pierre Meurant; Marie-Cécile Le Deley; Nicolas Penel Journal: BMC Cancer Date: 2018-07-31 Impact factor: 4.430
Authors: Samantha E Hoffman; Sally A Al Abdulmohsen; Saksham Gupta; Blake M Hauser; David M Meredith; Ian F Dunn; Wenya Linda Bi Journal: Front Neurol Date: 2020-07-08 Impact factor: 4.003